Molecular precursor lesions in oesophageal cancer - PubMed (original) (raw)
Affiliations
- PMID: 10489623
Review
Molecular precursor lesions in oesophageal cancer
R Montesano et al. Cancer Surv. 1998.
Abstract
Oesophageal cancer is the fifth most frequent cause of cancer death world wide and most of these cancers occur in developing countries. The survival rate for SCC or ADCs of the oesophagus is equally poor, mainly due to their late detection and the poor efficacy of the therapy. A short review of the natural history of these cancers, and in particular the occurrence of genetic and cellular alterations associated with cancer progression, is presented and discussed in the context of the relevance to aetiology and pathogenesis. SCCs and ADCs show a distinct pattern of TP53 mutations, namely a high prevalence of G > A transitions at CpG sites in ADCs whereas in SCCs a higher prevalence of G to T transversions and mutations at A:T base pairs is present. In both types of cancers TP53 mutations occur very early and are followed by the accumulation of other genetic alterations during the process of oesophageal carcinogenesis. The value of these genetic alterations in assessing the multifocal monoclonal origin of oesophageal cancer is also addressed.
Similar articles
- Molecular etiopathogenesis of esophageal cancers.
Montesano R, Hollstein M, Hainaut P. Montesano R, et al. Ann Ist Super Sanita. 1996;32(1):73-84. Ann Ist Super Sanita. 1996. PMID: 8967725 Review. - p53 Gene mutation and genetic instability in superficial multifocal esophageal squamous cell carcinoma.
Fujiki T, Haraoka S, Yoshioka S, Ohshima K, Iwashita A, Kikuchi M. Fujiki T, et al. Int J Oncol. 2002 Apr;20(4):669-79. Int J Oncol. 2002. PMID: 11894109 - CpG island hypermethylation in progression of esophageal and gastric cancer.
Sato F, Meltzer SJ. Sato F, et al. Cancer. 2006 Feb 1;106(3):483-93. doi: 10.1002/cncr.21657. Cancer. 2006. PMID: 16362978 Review. - Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma.
Roth MJ, Hu N, Emmert-Buck MR, Wang QH, Dawsey SM, Li G, Guo WJ, Zhang YZ, Taylor PR. Roth MJ, et al. Cancer Res. 2001 May 15;61(10):4098-104. Cancer Res. 2001. PMID: 11358832 - Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran.
Sepehr A, Tanière P, Martel-Planche G, Zia'ee AA, Rastgar-Jazii F, Yazdanbod M, Etemad-Moghadam G, Kamangar F, Saidi F, Hainaut P. Sepehr A, et al. Oncogene. 2001 Nov 1;20(50):7368-74. doi: 10.1038/sj.onc.1204912. Oncogene. 2001. PMID: 11704866
Cited by
- TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier M, Hollstein M, Hainaut P. Olivier M, et al. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. doi: 10.1101/cshperspect.a001008. Cold Spring Harb Perspect Biol. 2010. PMID: 20182602 Free PMC article. Review. - Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K. Park BB, et al. Invest New Drugs. 2008 Aug;26(4):387-92. doi: 10.1007/s10637-008-9126-3. Epub 2008 Mar 27. Invest New Drugs. 2008. PMID: 18368291 Clinical Trial. - Methylation in esophageal carcinogenesis.
Wu DL, Sui FY, Jiang XM, Jiang XH. Wu DL, et al. World J Gastroenterol. 2006 Nov 21;12(43):6933-40. doi: 10.3748/wjg.v12.i43.6933. World J Gastroenterol. 2006. PMID: 17109513 Free PMC article. Review. - Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.
Tanière P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F, Hainaut P. Tanière P, et al. Am J Pathol. 2001 Jan;158(1):33-40. doi: 10.1016/S0002-9440(10)63941-7. Am J Pathol. 2001. PMID: 11141476 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous